Breaking News Instant updates and real-time market news.

AMKR

Amkor Technology

$10.71

-0.71 (-6.22%)

, STAR

iStar

$11.54

0.12 (1.05%)

04:55
11/30/17
11/30
04:55
11/30/17
04:55

Bofa/Merrill to hold a conference

Leveraged Finance Conference is being held in Boca Raton, FL on November 29-30.

AMKR

Amkor Technology

$10.71

-0.71 (-6.22%)

STAR

iStar

$11.54

0.12 (1.05%)

BIOS

BioScrip

$2.51

-0.02 (-0.79%)

KTOS

Kratos Defense

$10.38

-0.2 (-1.89%)

CYH

Community Health

$4.45

0.26 (6.21%)

AXL

American Axle

$18.26

0.13 (0.72%)

BCO

Brink's

$81.20

-0.85 (-1.04%)

SM

SM Energy

$19.25

0.16 (0.84%)

SPN

Superior Energy

$9.37

0.14 (1.52%)

VSTO

Vista Outdoor

$14.53

0.19 (1.33%)

CDE

Coeur Mining

$7.63

-0.07 (-0.91%)

TNC

Tennant

$65.80

0.66 (1.01%)

NFX

Newfield Exploration

$30.10

0.18 (0.60%)

S

Sprint

  • 30

    Nov

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 11

    Dec

  • 14

    Dec

  • 16

    Jan

AMKR Amkor Technology
$10.71

-0.71 (-6.22%)

STAR iStar
$11.54

0.12 (1.05%)

04/05/17
JMPS
04/05/17
INITIATION
JMPS
Market Perform
iStar initiated with a Market Perform, valuation fair, says JMP Securities
JMP Securities analyst Steven DeLaney initiated iStar with a Market Perform saying valuation is fair.
BIOS BioScrip
$2.51

-0.02 (-0.79%)

06/26/17
BRRR
06/26/17
NO CHANGE
Target $3.5
BRRR
Outperform
BioScrip price target raised to $3.50 from $2 at Barrington
Barrington analyst Michael Petusky raised his price target for BioScrip to $3.50 citing increased conviction in the company's long-term potential following a non-deal roadshow. The analyst has a favorable view of new management and keeps an Outperform rating on the shares.
06/30/17
CHLM
06/30/17
NO CHANGE
Target $3.5
CHLM
Buy
BioScrip refinancing a positive despite 'unexpected' dilution, says Craig-Hallum
Craig-Hallum analyst Kevin Ellich noted that BioScrip's debt refinancing deal included a private placement of shares and in-the-money warrants, which was "was unexpected and disappointing." However, he views the refinancing as an incremental positive as it extends debt maturities and gives management more time to focus on their turnaround efforts. Ellich keeps a Buy rating on BioScrip shares and raised his price target to $3.50 from $2.50.
08/10/17
RHCO
08/10/17
UPGRADE
RHCO
Buy
BioScrip upgraded on multiple catalysts at SunTrust
As noted earlier, SunTrust upgraded BioScrip to Buy from Hold. As reasons for the upgrade, analyst David MacDonald cited "ongoing operational improvements, ramping collection/cash flow, solid conviction in new management's ability to execute and recent changes to the capital structure that removed an overhang." He also noted that the company's Q2 EBITDA and cash flow beat expectations, and he says that it could benefit from rate relief created by the Cure Act. Target to $3.75 from $3.25.
08/10/17
RHCO
08/10/17
UPGRADE
RHCO
Buy
BioScrip upgraded to Buy from Hold at SunTrust
KTOS Kratos Defense
$10.38

-0.2 (-1.89%)

11/01/17
ADAM
11/01/17
NO CHANGE
Target $15
ADAM
Buy
Kratos Defense report focus will be on backlog, says Canaccord
Canaccord analyst Ken Herbert previewed Kratos Defense's Q3 report and he expects the numbers to be in-line but for investors to focus on the company's backlog. Q2 showed a softer backlog due to the timing of awards so a step up is to be expected. The analyst does not expect guidance until the next quarterly call, but he views Kratos as a core holding for exposure to the defense budget cycle and specific areas of upside in unmanned systems, satellite communications, missile defense, and training. Herbert reiterated his Buy rating and $15 price target on Kratos Defense shares.
11/06/17
ADAM
11/06/17
NO CHANGE
Target $15
ADAM
Buy
Kratos Defense weakness attributed to capital raise speculation, says Canaccord
Canaccord analyst Ken Herbert noted Kratos Defense shares were weak following Q3 results as he heard a short reported had been circulating the company was planning to issue a convertible bond offering. Although he could not verify the existence of the report, he said management indicated they have no plans to issue any converts and the only planned balance sheet activity is its well-known debt refinance strategy that would cut about $100M of debt. Herbert reiterated his Buy rating and $15 price target on Kratos Defense shares.
11/08/17
ADAM
11/08/17
NO CHANGE
Target $15
ADAM
Buy
Kratos Defense note offering a net positive, says Canaccord
Canaccord analyst Ken Herbert believes the Kratos Defense note offering is a net positive as it will enable the company to retire all of its current 2019 outstanding debt while providing the company with more than $100M of cash to invest in organic growth opportunities. The analyst said the next challenge will be for the company to demonstrate that the better than expected top-line outlook can translate into the EBITDA and free cash flow that he believes is possible. Herbert reiterated his Buy rating and $15 price target on Kratos Defense shares.
08/15/17
08/15/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Kratos Defense (KTOS) initiated with a Buy at Drexel Hamilton. 2. PetIQ (PETQ) was initiated with an Outperform at Raymond James, William Blair, and Oppenheimer, while being initiated with a Buy at SunTrust and a Hold at Jefferies. 3. Donnelley Financial Solutions (DFIN) initiated with a Neutral at JPMorgan. 4. Calyxt (CLXT) initiated with a Buy at Citi. 5. Ecolab (ECL) initiated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CYH Community Health
$4.45

0.26 (6.21%)

11/06/17
CANT
11/06/17
NO CHANGE
CANT
Community Health target cut to $6 on Q3 miss at Cantor Fitzgerald
Cantor Fitzgerald analyst Joseph France lowered his price target for Community Health Systems to $6 from $7 citing the "disappointing" Q3 miss. The analyst reduced his estimates to reflect lower revenue trends and margin headwinds due to weak volumes, pressure on rates, and restructuring costs. Right-sizing Community Health and strengthening its capital structure is going to take a while, the analyst contends. He keeps a Neutral rating on the shares.
11/03/17
FBCO
11/03/17
INITIATION
Target $3.5
FBCO
Underperform
Community Health initiated with an Underperform at Credit Suisse
Credit Suisse analyst A.J. Rice started Community Health Systems with an Underperform rating and $3.50 price target.
08/28/17
JEFF
08/28/17
NO CHANGE
JEFF
Buy
HCA has 11% of its beds in Harvey impacted areas, says Jefferies
Jefferies analyst Brian Tanquilut points out that HCA Holdings (HCA) has 11% of its beds in areas impacted by severe weather from Hurricane Harvey. The analyst expects the hurricane to cause a "notable disruption," specifically for hospitals, physician offices, surgery centers, and labs. Investors are likely to take a long-term view of Hurricane Harvey, however, as it is a one-time issue and thus excluded from operating and financial results, Tanquilut tells investors in a research note. He sees both Tenet (THC) and Community Health (CYH) being minimally impacted from the storm. Envision Healthcare's (EVHC) AmSurg segment has three ambulatory surgery centers in the impacted markets, while Surgery Partners (SGRY) has only one facility in Houston, the analyst adds.
09/06/17
CANT
09/06/17
NO CHANGE
CANT
Overweight
Irma threat a risk for HCA, public hospital peers, says Cantor
Cantor Fitzgerald analyst Joseph France noted that HCA Holdings (HCA), Community Health (CYH), LifePoint (LPNT), Tenet (THC) and Envision Healthcare (EVHC) all have business in Florida and Texas and are all down today on the potential threat from Hurricane Irma and the impact from Hurricane Harvey last week. HCA reports nearly half of its beds are in Florida and Texas while Envision has said in the past that more than half of its anesthesia business and about half of its legacy ER business is in those two states, noted France, who adds that Community Health, LifePoint and Tenet are less exposed to those states. The analyst keeps an Overweight rating on HCA shares.
AXL American Axle
$18.26

0.13 (0.72%)

06/22/17
DBAB
06/22/17
DOWNGRADE
DBAB
Hold
Dana Holding downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Rod Lache downgraded Dana Holding (DAN) to Hold from Buy, noting that the stock has risen to within 5% of the firm's target. Looking at the broader space, he contends that the backdrop remains unfavorable for Auto/Auto Parts stocks, though select suppliers can outperform if SAAR moderates slowly. Lache maintains Buy ratings on BorgWarner (BWA), Delphi (DLPH), and American Axle (AXL), which he views as having favorable near-term set-ups.
06/21/17
GUGG
06/21/17
INITIATION
Target $18
GUGG
Buy
American Axle initiated with a Buy at Guggenheim
Guggenheim analyst Emmanuel Rosner started American Axle with a Buy rating and $18 price target.
10/12/17
DBAB
10/12/17
DOWNGRADE
Target $104
DBAB
Hold
Delphi downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Rod Lache downgraded Delphi Automotive (DLPH) to Hold and lowered his price target for the shares to $104 from $108. The analyst views the valuation as fair at current share levels and sees better opportunities elsewhere in the space. Lache prefers shares of General Motors (GM), American Axle (AXL) and Magna (MGA) for automotive exposure.
06/08/17
MSCO
06/08/17
NO CHANGE
MSCO
Morgan Stanley makes "big" cuts to US Auto Sales forecasts
Morgan Stanley analyst Adam Jonas made "big" cuts to his US auto industry sales forecast, reducing his 2017 US SAAR forecast to 17.3M units from 18.3M units, 2018 to 16.4M units from 18.9M units, 2019 to 15M units from 19.2M units, and 2020 to 15M units from 18.7M units. Jonas believes the auto cycle may be hitting a point of diminishing returns following 8 years into the biggest cycle on record as used car values erode, pressuring conditions for selling new vehicles, and said new vehicle inventory levels continue to rise. Additionally, the analyst expects electrical margins to face increasing competition from new entrants and higher development costs. As a result, Jonas cut estimates across the board and downgraded Lear (LEA) to Underweight from Equal Weight.
BCO Brink's
$81.20

-0.85 (-1.04%)

08/09/17
IMPC
08/09/17
UPGRADE
Target $86
IMPC
Outperform
Brink's upgraded to Outperform from In-Line at Imperial Capital
Imperial Capital analyst Jeff Kessler upgraded The Brink's Company to Outperform and raised his price target for the shares to $86 from $72. The analyst says investors have "much to be bullish about" in the second half of 2017 following the company's "strong" first half results and recent acquisitions.
10/18/17
RHCO
10/18/17
NO CHANGE
Target $98
RHCO
Buy
Brink's price target raised to $98 from $92 at SunTrust
SunTrust analyst Tobey Sommer raised his price target on Brink's to $98, saying the risks of a potential Canadian strike are overblown while the prospects of moving to two employees per truck staffing are positive. Sommer notes that there is a misperception of a demise in the use of cash, as the latest Federal Reserve data suggests the USD currency in circulation has increased 7.4% year-on-year. The analyst also has a positive view of the recent appointment of a new head of U.S. operations, maintaining his Buy rating on Brink's.
10/20/17
SIDC
10/20/17
INITIATION
SIDC
Buy
Brink's initiated with a Buy at Sidoti
08/09/17
08/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Neutral from Sell at Goldman Sachs with analyst Waqar Syed saying Transocean has enhanced the balance sheet over the past several months and now sees leveraged metrics to be relatively better than the peer group in the 2019/2020 time frame. 2. Ralph Lauren (RL) upgraded to Neutral from Underweight at Atlantic Equities. 3. Brink's (BCO) upgraded to Outperform from In-Line at Imperial Capital with analyst Jeff Kessler saying investors have "much to be bullish about" in the second half of 2017 following the company's "strong" first half results and recent acquisitions. 4. Novavax (NVAX) upgraded to Buy from Neutral at Ladenburg with analyst Kevin Degeeter saying he believes the company's NanoFlu could become a "potent vaccine" for prevention of seasonal influenza. 5. Esperion (ESPR) upgraded to Buy from Hold at Jefferies with analyst Michael Yee saying the shares are likely "to keep grinding higher and higher" following the "new de-risking data" for the triple combination. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SM SM Energy
$19.25

0.16 (0.84%)

07/19/17
BOFA
07/19/17
INITIATION
Target $20
BOFA
Neutral
SM Energy reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Asit Sen reinstated SM Energy with a Hold and a $20 price target.
10/23/17
JPMS
10/23/17
UPGRADE
Target $30
JPMS
Overweight
SM Energy upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Michael Glick upgraded SM Energy to Overweight following a "deep dive" into the Powder River Basin and Howard County. The analyst sees "potentially substantial value" in the Powder asset and views SM as a top beta pick in the small-to-mid Exploration and Production space. He raised his price target for the shares to $30 from $22.
06/21/17
GHSC
06/21/17
DOWNGRADE
GHSC
Neutral
SM Energy downgraded to Neutral from Buy at Seaport Global
06/01/17
FBCO
06/01/17
INITIATION
Target $30
FBCO
Outperform
SM Energy initiated with an Outperform at Credit Suisse
Credit Suisse analyst Nitin Kumar initiated SM Energy with an Outperform and a $30 price target.
SPN Superior Energy
$9.37

0.14 (1.52%)

11/21/17
RHCO
11/21/17
UPGRADE
Target $13
RHCO
Buy
Superior Energy upgraded to Buy at SunTrust on pricing and demand improvement
As reported earlier, SunTrust analyst Ken Sill upgraded Superior Energy to Buy from Hold and raised his price target to $13 from $12. Sill says that while the company's U.S. completion rate has lagged that of its peers, improved pricing trends and higher customer demand will result in better completions over the next few quarters, as Superior Energy reprices fleets to higher market rates and more favorable contract terms. The analyst also notes the company's attractive valuation, saying his price target places it around the average of Superior's EV/EBITDA 2008-2015 range.
11/20/17
RHCO
11/20/17
UPGRADE
RHCO
Buy
Superior Energy upgraded to Buy from Hold at SunTrust
11/17/17
WELS
11/17/17
NO CHANGE
WELS
Wells elevates C&J to top pick in Pressure Pumping
With higher oil prices and a tight supply/demand balance, the Pressure Pumping market remains one of the most attractive segments in Oil Services & Equipment, Wells Fargo analyst Judson Bailey tells investors in a research note. After looking at valuations post the Q3 earnings reports, the analyst elevates C&J Energy Services (CJ) to his top pick in the space. Following C&J are Keane Group (FRAC), Patterson-UTI (PTEN), RPC, Inc. (RES) and Superior Energy (SPN).
10/25/17
LOOP
10/25/17
NO CHANGE
Target $13
LOOP
Buy
Superior Energy price target lowered to $13 from $18 at Loop Capital
Loop Capital analyst Stephen Gengaro lowered his price target on Superior Energy to $13 after "mixed" Q3 performance, as results in the U.S. land market lagged. Gengaro says valuation multiples will face headwinds until more consistent results are produced, but also maintains a Buy rating given the "very favorable" risk-reward at current levels.
VSTO Vista Outdoor
$14.53

0.19 (1.33%)

08/21/17
AGIS
08/21/17
INITIATION
Target $26
AGIS
Hold
Vista Outdoor initiated with a Hold at Aegis
Aegis analyst Rommel Dionisio initiated Vista Outdoor with a Hold and a $26 price target.
08/30/17
KEYB
08/30/17
INITIATION
KEYB
Sector Weight
Vista Outdoor resumed with a Sector Weight from Overweight at KeyBanc
KeyBanc analyst Brett Andress resumed coverage of Vista Outdoor with a Sector Weight rating. The firm previously had an Overweight rating on the name.
10/06/17
ROTH
10/06/17
NO CHANGE
Target $21
ROTH
Neutral
New CEO to tackle distribution concerns at Vista Outdoor, says Roth Capital
Roth Capital analyst Dave King says that despite the announcement of a new CEO hire by Vista Outdoor (VSTO), he still remains concerned about the "sustainability of Vista's distribution competitive advantage" and soft performance from recent acquisitions. King writes that incoming CEO Chris Metz brings extensive experience in driving operational improvements, as the company continues to focus on expanding its e-commerce presence and possibly grow its business with Amazon (AMZN). The analyst is also positive on the opportunity to capture market share in the ammo downturn, maintaining a Neutral rating and his $21 price target on Vista.
11/09/17
DADA
11/09/17
DOWNGRADE
Target $14
DADA
Neutral
Vista Outdoor downgraded to Neutral from Buy at DA Davidson
DA Davidson analyst Andrew Burns downgraded Vista Outdoor to Neutral and cut his price target for the shares to $14 from $29 following the company's Q2 results.
CDE Coeur Mining
$7.63

-0.07 (-0.91%)

11/17/17
BMOC
11/17/17
INITIATION
Target $10.5
BMOC
Outperform
Coeur Mining initiated with an Outperform at BMO Capital
BMO Capital analyst Ryan Thompson initiated Coeur Mining with an Outperform rating and a $10.50 price target. Thompson says shares are poised to move higher in light of the recommencement of production at the newly-added high-grade Silvertip mine and future mining from the high-grade Jualin deposit at Kensington. The analyst also says the company offers "one of the best production growth profiles in the peer group" at an attractive cash flow per share valuation.
10/27/17
ROTH
10/27/17
NO CHANGE
Target $10.5
ROTH
Buy
Coeur Mining price target lowered to $10.50 from $12.50 at Roth Capital
Roth Capital analyst Joe Reagor noted that Coeur Mining raised its cost guidance along with its "mixed" Q3 report, adding that he sees risk to the company missing its cost guidance at San Bartolome and Rochester. Reagor, who also lowered his near-term forward precious metals price forecasts, cut his price target on Coeur shares to $10.50 from $12.50, but said he views the recent selloff as an "overreaction" to minor issues and keeps a Buy rating on the stock.
11/21/17
RAJA
11/21/17
UPGRADE
Target $10.5
RAJA
Outperform
Coeur Mining upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Brian MacArthur upgraded Coeur Mining to Outperform and raised its price target to $10.50 from $10.25 following the recent pullback in shares.
09/12/17
BMOC
09/12/17
NO CHANGE
BMOC
Coeur Mining acquisition positive, says BMO Capital
BMO Capital analyst Andrew Kalp says that Coeur Mining's acquisition of Silvertip is positive because it "is a high grade deposit that comes with a large, unexplored land package in a good juridiction." The analyst thinks that the company can find more minerals there, and he views the purchase price as "fair." He thinks the deal will boost the company's margins and keeps an $11 price target and an Outperform rating on the stock.
TNC Tennant
$65.80

0.66 (1.01%)

NFX Newfield Exploration
$30.10

0.18 (0.60%)

10/13/17
BMOC
10/13/17
DOWNGRADE
Target $32
BMOC
Market Perform
Newfield downgraded to Market Perform with $32 target at BMO Capital
BMO Capital analyst Dan McSpirit downgraded Newfield Exploration (NFX) to Market Perform from Outperform and lowered his price target for the shares to $32 from $34. The analyst sees a "less compelling value proposition" at current trading levels after reviewing recent well results. He sees a more attractive risk/reward in shares of Diamondback Energy (FANG).
06/21/17
GHSC
06/21/17
DOWNGRADE
Target $24
GHSC
Sell
Newfield Exploration downgraded to Sell from Buy at Seaport Global
Seaport Global analyst Mike Kelly downgraded Newfield to Sell from Buy and slashed its price target to $24 from $50 to reflect a new commodity price deck. Seaport Global's Energy team reduced its long-term oil forecast to $40/bbl from $50/bbl to reflect "relentless" US production growth. The firm sees the potential for the oil market to be "significantly over supplied in 2018 and cut its oil price forecast for first half 2017 to $45/bbl from $55/bbl and first half 2018 to $35/bbl from $55/bbl.
08/29/17
JEFF
08/29/17
NO CHANGE
Target $25
JEFF
Buy
Jefferies cuts oil forecast, Exploration & Production price targets
Jefferies lowered its Brent estimate to $57 per barrel from $64 in 2018, to $60 from $67 in 2019, and to $65 from $70 in 2020. The market appears to be adequately supplied in the near term, but depleting proved developed reserves and shrinking spare capacity should support rising longer-term price assumption, analyst Michael Hsu tells investors in a research note. To reflect the reduced forecast, the analyst cut his price targets for names in the Exploration & Production space. Target cuts include Buy-rated Carrizo Oil & Gas (CRZO) to $25 from $32, Buy-rated Continental Resources (CLR) to $42 from $52, Buy-rated Newfield Exploration (NFX) to $40 from $46, Buy-rated Noble Energy (NBL) to $32 from $36, Buy-rated Oasis Petroleum (OAS) to $13 from $16, Buy-rated Pioneer Natural Resources (PXD) to $171 from $192 and Buy-rated Range Resources (RRC) to $36 from $37.
10/13/17
BMOC
10/13/17
DOWNGRADE
BMOC
Market Perform
Newfield Exploration downgraded to Market Perform at BMO Capital
S Sprint

11/06/17
11/06/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Weatherford (WFT) downgraded to Neutral from Buy at Citi with analyst Scott Gruber saying the company's turnaround is going to take time and the ending remains uncertain. 2. Hyatt (H) downgraded to Neutral from Buy at B. Riley FBR with analyst Bryan Maher citing valuation following the stock's recent rally. 3. Sprint (S) downgraded to Underweight from Sector Weight at KeyBanc with analyst Brandon Nispel saying competitive intensity in the wireless industry will likely increase now that the company could not reach a merger agreement with T-Mobile (TMUS). 4. Goldman Sachs (GS) downgraded to Sell from Hold at Vertical Group with analyst Richard Bove saying "more earnings issues may surface" as the company continues to pursue its traditional business model when it is evident it is no longer relevant. 5. Hilton (HLT) downgraded to Market Perform from Outperform at Wells Fargo with analyst Jeffrey Donnelly citing the stock's "premium valuation" and a lack of visible catalysts. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/27/17
KEYB
11/27/17
NO CHANGE
Target $192
KEYB
Overweight
SBA Communications price target raised to $192 from $179 at KeyBanc
KeyBanc analyst Brandon Nispel raised his price target for SBA Communications (SBAC) to $192 from $179 to reflect potential contribution from Sprint (S) as well as his belief that FirstNet could also be a contributor in 2019. The analyst reiterates an Overweight rating on SBA Communications' shares.
11/27/17
KEYB
11/27/17
NO CHANGE
Target $177
KEYB
Overweight
American Tower price target raised to $177 from $156 at KeyBanc
KeyBanc analyst Brandon Nispel raised his price target for American Tower (AMT) to $177 from $156 and raised his 2018 U.S. new leasing activity to reflect potential activity from Sprint (S). The analyst reiterates an Overweight rating on American Tower's shares.
11/09/17
ARGS
11/09/17
NO CHANGE
Target $170
ARGS
Buy
American Tower price target raised to $170 from $150 at Argus
Argus analyst Jacob Kilstein raised his price target on American Tower to $170 and kept his Buy rating. Kilstein says the company stands out among tower operators based on its margins, FFO growth rates, and high-quality assets, while also noting its international expansion steps. Additionally, the analyst says that the company stands to benefit from receding risks of telecom industry consolidation, as evidenced by the 6% jump in stock price when Sprint (S) and T-Mobile (TMUS) announced an end of their merger talks.

TODAY'S FREE FLY STORIES

BPMP

BP Midstream

$18.00

0.07 (0.39%)

07:20
12/15/17
12/15
07:20
12/15/17
07:20
Initiation
BP Midstream initiated  »

BP Midstream initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:20
12/15/17
12/15
07:20
12/15/17
07:20
General news
FX Update: The dollar has been trading mostly softer »

FX Update: The dollar…

CSII

Cardiovascular Systems

$24.73

-0.26 (-1.04%)

07:20
12/15/17
12/15
07:20
12/15/17
07:20
Downgrade
Cardiovascular Systems rating change  »

Cardiovascular Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$255.48

-0.08 (-0.03%)

, JPM

JPMorgan

$104.66

-0.85 (-0.81%)

07:19
12/15/17
12/15
07:19
12/15/17
07:19
Periodicals
London-based investment banks to face tighter EU control, Reuters reports »

Large London-based…

GS

Goldman Sachs

$255.48

-0.08 (-0.03%)

JPM

JPMorgan

$104.66

-0.85 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

CRTO

Criteo

$24.42

-7.19 (-22.75%)

07:19
12/15/17
12/15
07:19
12/15/17
07:19
Upgrade
Criteo rating change  »

Criteo upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$175.00

-1.83 (-1.03%)

07:15
12/15/17
12/15
07:15
12/15/17
07:15
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIGL

Rigel Pharmaceuticals

$3.57

-0.15 (-4.03%)

07:14
12/15/17
12/15
07:14
12/15/17
07:14
Initiation
Rigel Pharmaceuticals initiated  »

Cantor sees FDA approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

CRTO

Criteo

$24.42

-7.19 (-22.75%)

07:12
12/15/17
12/15
07:12
12/15/17
07:12
Downgrade
Criteo rating change  »

Criteo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$50.19

0.14 (0.28%)

07:11
12/15/17
12/15
07:11
12/15/17
07:11
Recommendations
Oracle analyst commentary  »

Oracle business momentum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIPR

Innovative Industrial Properties

$22.60

2.28 (11.22%)

07:10
12/15/17
12/15
07:10
12/15/17
07:10
Hot Stocks
Innovative Industrial Properties raises quarterly dividend to 25c per share »

Innovative Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLX

Hologic

$42.96

-0.72 (-1.65%)

07:08
12/15/17
12/15
07:08
12/15/17
07:08
Recommendations
Hologic analyst commentary  »

Hologic positioned well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFGC

Performance Food Group

$30.55

-0.9 (-2.86%)

07:07
12/15/17
12/15
07:07
12/15/17
07:07
Earnings
Performance Food Group sees FY18 adjusted EPS up 13%-18% »

For fiscal 2018, PFG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

TYME

Tyme Technologies

$3.30

0.05 (1.54%)

07:05
12/15/17
12/15
07:05
12/15/17
07:05
Initiation
Tyme Technologies initiated  »

Tyme Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

, SNY

Sanofi

$43.09

-0.83 (-1.89%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Hot Stocks
Alnylam announces lift of FDA clinical hold on Fitusiran »

Alnylam Pharmaceuticals…

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

SNY

Sanofi

$43.09

-0.83 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

  • 02

    May

UA

Under Armour; also tag UAA

$12.45

0.09 (0.73%)

, UAA

Under Armour; also tag UA

$13.82

0.2 (1.47%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Upgrade
Under Armour; also tag UAA, Under Armour; also tag UA rating change  »

Under Armour upgraded to…

UA

Under Armour; also tag UAA

$12.45

0.09 (0.73%)

UAA

Under Armour; also tag UA

$13.82

0.2 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBA

Ritchie Bros.

$28.69

0.3 (1.06%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Hot Stocks
Ritchie Bros. sess $50M+ of equipment in final Fort Worth, TX auction of 2017 »

This week Ritchie Bros.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$43.09

-0.83 (-1.89%)

, ALNY

Alnylam

$123.66

-1.2 (-0.96%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
Sanofi says FDA lifts clinical hold on fitusiran »

Sanofi Genzyme, the…

SNY

Sanofi

$43.09

-0.83 (-1.89%)

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

  • 02

    May

CROX

Crocs

$10.94

-0.34 (-3.01%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Upgrade
Crocs rating change  »

Crocs upgraded to Buy on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 08

    Jan

ESNC

EnSync

$0.44

0.0663 (17.79%)

, CHTR

Charter

$328.68

-0.32 (-0.10%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
EnSync: Spectrum solar plus storage project commissioned in Hawaii »

EnSync (ESNC) announces…

ESNC

EnSync

$0.44

0.0663 (17.79%)

CHTR

Charter

$328.68

-0.32 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

PFGC

Performance Food Group

$30.55

-0.9 (-2.86%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
Performance Food Group appoints Jim Hope as CFO »

Performance Food Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

ACRS

Aclaris Therapeutics

$24.72

-0.38 (-1.51%)

07:02
12/15/17
12/15
07:02
12/15/17
07:02
Hot Stocks
Aclaris Therapeutics receives FDA approval for Eskata topical solution, 40% »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Dec

AER

AerCap

$52.12

-0.46 (-0.87%)

07:01
12/15/17
12/15
07:01
12/15/17
07:01
Recommendations
AerCap analyst commentary  »

AerCap book value can hit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTWO

Q2 Holdings

$37.30

-0.75 (-1.97%)

07:00
12/15/17
12/15
07:00
12/15/17
07:00
Recommendations
Q2 Holdings analyst commentary  »

Q2 Holdings has strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

07:00
12/15/17
12/15
07:00
12/15/17
07:00
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

$6.82

-0.2 (-2.85%)

06:59
12/15/17
12/15
06:59
12/15/17
06:59
Downgrade
Fitbit rating change  »

Fitbit downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.